Ophthalmology Contract Research Organization (CRO) Market Size - Service Type (Clinical Research Services {Phase I, Phase II}), Therapy (Traditional, Advanced), End-use, Global Forecast, 2023

Description

List of Tables

Global Ophthalmology Contract Research Organization (CRO) Market will witness 7.3% CAGR between 2023 and 2032. The industry is thriving due to the growing number of collaborations between leading companies.

For instance, in July 2023, Ora, a Clinical Research Organization (CRO) specializing in ophthalmology pharmaceutical and device development, joined forces with the Northwest London Clinical Trials Alliance to enhance the quality and accessibility of clinical research in the region. This strategic partnership is particularly significant as it aligns with the UK government's emphasis on the value of innovative collaboration across multiple sectors, marking a crucial juncture in time. These partnerships have propelled research and development efforts, fostering innovation and expediting clinical trials for eye-related treatments. This collaborative approach not only accelerates progress but also optimizes resources, making it a pivotal factor in boosting ophthalmology CRO market growth.

The overall Ophthalmology Contract Research Organization (CRO) Market is classified based on service type, end-use, and region.

Early phase development services segment will undergo appreciable development from 2023 to 2032. As advancements in eye-related treatments continue to evolve, pharmaceutical and device companies are eager to accelerate their research. Early phase CRO services offer crucial support in this phase, facilitating safety and efficacy assessments, ultimately driving innovation and efficiency in the ophthalmic field, thus strengthening the ophthalmology contract research organization market outlook.

Medical devices companies segment will register a notable CAGR from 2023 to 2032, driven by the rising need for rigorous testing and clinical evaluation of ophthalmic devices to ensure safety and efficacy. As the field of ophthalmology continues to innovate, CROs play a pivotal role in helping medical device companies navigate regulatory hurdles, expedite product development, and meet the escalating demand for cutting-edge eye-related technologies. Therefore, the rising innovations in medical devices support the ophthalmology contract research organization industry dynamics.

Europe ophthalmology contract research organization (CRO) market will showcase a noteworthy CAGR from 2023 to 2032. With a growing aging population and increasing eye-related ailments, the region's pharmaceutical and medical device industries are seeking CRO support to advance research and development efforts. Europe's commitment to cutting-edge ophthalmic treatments is fueling the expansion of the CRO market in the region.

Product Code: 6617

Chapter 1 Methodology & Scope

1.1 Market definition & scope
1.2 Base estimates & calculations
- 1.2.1 Data collection
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Global ophthalmology contract research organization (CRO) industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Service type trends
- 2.1.4 Therapy trends
- 2.1.5 End-use trends

Chapter 3 Ophthalmology Contract Research Organization (CRO) Industry Insights

3.1 Industry segmentation
3.2 Industry landscape, 2018 - 2032 (USD Million)
3.3 Industry impact forces
- 3.3.1 Growth drivers
  - 3.3.1.1 Rising prevalence of eye disorders
  - 3.3.1.2 Increasing outsourcing for ophthalmology R&D activities
  - 3.3.1.3 Increasing demand for novel ophthalmic therapies
- 3.3.2 Industry pitfalls & challenges
  - 3.3.2.1 Varying regulatory requirements across regions
3.4 Growth potential analysis
- 3.4.1 By service type
- 3.4.2 By therapy
- 3.4.3 By end-use
3.5 COVID-19 impact analysis
3.6 Ophthalmology clinical trial analysis
- 3.6.1 Ophthalmology clinical trial volume, by region, 2018 - 2022
- 3.6.2 Ophthalmology clinical trial volume, by indication, 2018 - 2022
- 3.6.3 Ophthalmology clinical trial volume, by phase of development, 2018 - 2022
3.7 Regulatory landscape
- 3.7.1 U.S.
- 3.7.2 Europe
3.8 Drug discovery and development process
3.9 Porter's analysis
3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Company positioning matrix
4.4 Strategy dashboard, 2022

Chapter 5 Ophthalmology Contract Research Organization (CRO) Market, By Service Type, 2018 - 2032 (USD Million)

5.1 Key trends, by service type
5.2 Early phase development services
5.3 Clinical research
- 5.3.1 Phase I
- 5.3.2 Phase II
- 5.3.3 Phase III
- 5.3.4 Phase IV
5.4 Laboratory services
5.5 Regulatory consulting services

Chapter 6 Ophthalmology Contract Research Organization (CRO) Market, By Therapy, 2018 - 2032 (USD Million)

6.1 Key trends, by therapy
6.2 Traditional interventions
- 6.2.1 Anti-inflammatory interventions
  - 6.2.1.1 Corticosteroids
  - 6.2.1.2 NSAIDs
  - 6.2.1.3 Immunomodulators
  - 6.2.1.4 Other anti-inflammatory interventions
- 6.2.2 Anti-oxidative interventions
- 6.2.3 Other traditional interventions
6.3 Advanced interventions
- 6.3.1 Cell therapy
- 6.3.2 Gene theray
- 6.3.3 Other advanced interventions

Chapter 7 Ophthalmology Contract Research Organization (CRO) Market, By End-user, 2018 - 2032 (USD Million)

7.1 Key trends, by end-user
7.2 Pharma/biopharma companies
7.3 Medical device companies
7.4 Academic institutes

Chapter 8 Ophthalmology Contract Research Organization (CRO) Market, By Region, 2018 - 2032 (USD Million)

8.1 Key trends, by region
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 MEA
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 Rest of MEA

Chapter 9 Company Profiles

9.1 Charles River Laboratories International, Inc.
9.2 ICON plc
9.3 Laboratory Corporation of America Holdings (Covance Inc.)
9.4 Medpace, Inc.
9.5 Pharmaceutical Product Development (Thermo Fisher Scientific, Inc.)
9.6 Syneos Health
9.7 Worldwide Clinical Trials
9.8 WuXi AppTec
9.9 ORA Inc.
9.10 CTRG (Clinical Trial Resource Group)
9.11 Iris Pharma
9.12 Trial Runners
9.13 The Emmes Company, LLC
9.14 Lexitas Pharma Services, Inc.
9.15 ProTrial Research, Inc.
9.16 TFS HealthScience